drugset / Trial / NCT04573023
A Phase III Study of JR-141 in Patients With Mucopolysaccharidosis II (STARLIGHT)
RandomizedParallel-groupSingle-blindTreatment
Summary
A Global Phase III multicenter, randomized, assessor-blinded, active-controlled designed to evaluate safety and efficacy of study drug for the treatment of the MPS II.
Timeline
- Start
- 2022-02-14
- Primary completion
- 2027-10-31
- Completion
- 2027-10-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PABINAFUSP ALFA | Protein / enzyme biologic | 2 mg/kg | Intravenous |
| Subject | idursulfase | Protein / enzyme biologic | — | Intravenous |